[go: up one dir, main page]

RS51271B - Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid - Google Patents

Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid

Info

Publication number
RS51271B
RS51271B RSP-2009/0048A RSP20090048A RS51271B RS 51271 B RS51271 B RS 51271B RS P20090048 A RSP20090048 A RS P20090048A RS 51271 B RS51271 B RS 51271B
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
solid pharmaceutical
donepezil hydrochloride
donepezil
hydrochloride
Prior art date
Application number
RSP-2009/0048A
Other languages
English (en)
Inventor
Miha Vrbinc
Berta Kotar-Jordan
Rok Zupet
Matej Smrkolj
Original Assignee
Krka Tovarna Zdravil D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51271(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil D.D. filed Critical Krka Tovarna Zdravil D.D.
Publication of RS51271B publication Critical patent/RS51271B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Čvrsta farmaceutska kompozicija donepezil hidrohlorida u obliku hidrata i ekscipienasa, koja sadrži 3 do mas. 10 % vode (odredjivano po Karl Fischer).Prijava sadrži još 18 patentnih zahteva.
RSP-2009/0048A 2004-10-19 2005-10-19 Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid RS51271B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19

Publications (1)

Publication Number Publication Date
RS51271B true RS51271B (sr) 2010-12-31

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0048A RS51271B (sr) 2004-10-19 2005-10-19 Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid

Country Status (19)

Country Link
US (3) US20090130205A9 (sr)
EP (3) EP2039349A1 (sr)
JP (1) JP2008517022A (sr)
AT (1) ATE415148T1 (sr)
CA (1) CA2584547C (sr)
CY (1) CY1109956T1 (sr)
DE (1) DE602005011326D1 (sr)
DK (1) DK1811957T3 (sr)
EA (1) EA012220B1 (sr)
ES (1) ES2317313T3 (sr)
HR (1) HRP20090104T3 (sr)
NO (1) NO20072494L (sr)
PL (1) PL1811957T3 (sr)
PT (1) PT1811957E (sr)
RS (1) RS51271B (sr)
SI (1) SI1811957T1 (sr)
UA (1) UA83152C2 (sr)
WO (1) WO2006045512A1 (sr)
ZA (1) ZA200704023B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
WO2008092011A2 (en) * 2007-01-24 2008-07-31 Cook Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
SG190406A1 (en) * 2010-11-30 2013-06-28 Wista Lab Ltd Formulations comprising methylthioninium chloride
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20150216849A1 (en) 2014-02-04 2015-08-06 Forest Laboratories Holdings Ltd. Donepezil compositions and methods of treating alzheimers disease
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
CA2252806C (en) * 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US6390821B1 (en) * 1997-02-07 2002-05-21 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO1999042599A1 (en) * 1998-02-19 1999-08-26 Sapporo Breweries Ltd. Isolated and purified nucleic acids comprising a gene specifically expressed in hop glands
EP1086706B1 (en) 1999-03-31 2003-11-26 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1260215T3 (da) * 2000-03-01 2009-11-09 Eisai R&D Man Co Ltd Hurtig disintegrerende tablet indeholdende polyvinylalkohol
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (sr) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
CY1109956T1 (el) 2014-09-10
PL1811957T3 (pl) 2009-05-29
ZA200704023B (en) 2008-04-30
UA83152C2 (ru) 2008-06-10
WO2006045512A1 (en) 2006-05-04
HRP20090104T3 (en) 2009-03-31
US20090130205A9 (en) 2009-05-21
SI1811957T1 (sl) 2009-04-30
ATE415148T1 (de) 2008-12-15
JP2008517022A (ja) 2008-05-22
EP2283811A1 (en) 2011-02-16
CA2584547A1 (en) 2006-05-04
EA012220B1 (ru) 2009-08-28
NO20072494L (no) 2007-07-02
US20100317694A1 (en) 2010-12-16
DE602005011326D1 (de) 2009-01-08
EP1811957B1 (en) 2008-11-26
ES2317313T3 (es) 2009-04-16
EA200700673A1 (ru) 2007-10-26
PT1811957E (pt) 2009-01-27
US20120283291A1 (en) 2012-11-08
EP1811957A1 (en) 2007-08-01
CA2584547C (en) 2014-07-08
DK1811957T3 (da) 2009-03-30
EP2039349A1 (en) 2009-03-25
US20080063705A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
HRP20090104T3 (en) Solid pharmaceutical composition comprising donepezil hydrochloride
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EP1871334A4 (en) SKIN WHITENING LOTIONS
RS51563B (sr) Farmaceutske kompozicije koje sadrže rozuvastatin kalcijum
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20091395L (no) Nye tiofenderivater
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200870019A1 (ru) Лактамовые соединения и способы их применения
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
RS52169B (sr) Stabilni preparati lakvinimoda
EA201100129A1 (ru) Композиции и способы применения модулятора рецептора 5ht-2c
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
SE0402762D0 (sv) Indazole sulphonamide derivatives
AR109263A2 (es) Composición que comprende moxidectina
SE9900961D0 (sv) Novel compounds
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
SE0401970D0 (sv) Novel compounds
CR10495A (es) Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden